| 证券代码：603538 | 证券简称：美诺华 公告编号：2023-083 | | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | 宁波美诺华药业股份有限公司 关于全资子公司获得药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的厄贝沙坦片《药品补充申请批准通知书》， 现将相关情况公告如下： 一、药品相关信息 1、药品名称：厄贝沙坦片 2、剂型：片剂 4、申请内容：其他：药品上市许可持有人由"江西施美药业有限公司(地址: 江西省抚州市东乡区大富工业园区)"变更为"宁波美诺华天康药业有限公 司(地址：宁波大榭开发区滨海西路 85 号)"。 5、注册分类：化学药品 6、受理号：CYHB2301713 10、生产企业：江西施美药业股份有限公司 11、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， ...

根据《长期贷款合同》中关于担保事项的约定："借款人以现有全部土地使 用权、房屋所有权以及 1 号、2 号生产车间的生产设备抵押给贷款人，并承诺在 协议约定时间内对新建 3 号车间后新增的房屋所有权以及 3 号车间的生产设备 （最终以满足本协议双方约定的标准和目的的设备清单为准）办理补充抵押登 记。同时，公司为上述借款提供连带责任保证担保"。 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2023-082 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于子公司接受关联方长期贷款并由公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2020 年 2 月 17 日，宁波美诺华药业股份有限公司（以下简称"公司"）召 开 2020 年第一次临时股东大会，审议通过了《关于子公司接受关联方长期贷款 并由公司提供担保的议案》，同意公司全资子公司宁波美诺华天康药业有限公司 （以下简称"美诺华天康"或"借款人"）与宁波科 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2023, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[19]. - The company's operating revenue for the first half of 2023 was ¥582.26 million, a decrease of 35.11% compared to ¥897.31 million in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2023 was ¥30.85 million, down 83.29% from ¥184.66 million year-on-year[20]. - Basic earnings per share for the first half of 2023 were ¥0.14, down 83.90% from ¥0.87 in the same period last year[21]. - The company's total assets at the end of the reporting period were ¥4.33 billion, a decrease of 2.01% from ¥4.42 billion at the end of the previous year[20]. - The company's total liabilities decreased to ¥1,187,841,527.62 from ¥1,309,811,496.39, reflecting a reduction of 9.3%[159]. - The total equity decreased to ¥1,005,782,283.13, down 6.2% from ¥1,072,103,637.37 year-on-year[159]. Research and Development - The company’s R&D expenditure accounted for 10% of total revenue, reflecting its commitment to innovation and new product development[19]. - The company has filed 2 patent applications and received 8 authorized patents during the reporting period, bringing the total authorized patents to 152, including 70 invention patents[46]. - The company has developed a high-end research and development platform with over 14,000 square meters of laboratory space, focusing on innovative drug and material technologies[44]. - Research and development expenses were ¥35,627,084.03, down 19.2% from ¥44,110,760.17 in the previous year[161]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[19]. - New product launches are expected to contribute an additional RMB 200 million in revenue for the second half of 2023[19]. - The company has initiated a strategic partnership with KRKA, aiming to enhance its product offerings and distribution channels[19]. - The company is focusing on a dual strategy of "internal growth and external expansion" to enhance its integrated business model of intermediates, APIs, and formulations[34]. Financial Management and Cash Flow - The net cash flow from operating activities was -¥79.13 million, a decline of 152.56% compared to ¥150.54 million in the previous year[20]. - The company reported a net cash flow from investment activities of CNY -53.74 million, a decrease of 56.44% year-on-year, mainly due to reduced investment in financial products[66]. - The net cash flow from financing activities was CNY -64.04 million, a significant decline of 629.65%, primarily due to the repayment of bank loans[67]. - Cash and cash equivalents decreased by 21.56% to CNY 621.22 million, mainly due to reduced operating revenue and loan repayments[70]. Environmental and Quality Management - The company has established a comprehensive cGMP standard quality system, ensuring compliance with international quality standards and passing multiple audits from global pharmaceutical companies[39]. - The company has implemented an EHS management system to reduce safety and environmental risks associated with production processes[81]. - The company reported that actual wastewater discharge for chemical oxygen demand was 22.12 tons/year, significantly below the permitted limit of 112.20 tons/year[95]. - The company has established a comprehensive environmental monitoring system, ensuring compliance with pollution discharge standards through real-time monitoring[100]. Shareholder and Equity Management - The company held one shareholders' meeting during the reporting period, which complied with legal regulations[88]. - The company proposed a profit distribution plan of 10 shares for every 10 shares held, with a cash dividend of 10 yuan per share (including tax)[90]. - The company reported a total of 22,200,000 RMB in related party transactions, with actual transactions amounting to 9,155,150 RMB[106]. - The largest shareholder, Ningbo Meinuohua Holdings Group, holds 45,285,661 shares, representing 21.22% of the total shares[123]. Risk Management - The company is focused on increasing R&D investment and attracting talented personnel to improve the success rate of product development[82]. - The company anticipates potential risks from fixed asset depreciation as new projects come online, which may impact future profitability[82]. - The company has strengthened its quality management system, passing 7 official inspections and 34 customer audits during the reporting period[63]. Industry Outlook - The global pharmaceutical market is expected to grow at a compound annual growth rate of 3%-6% from 2023 to 2027, reaching approximately $1.9 trillion[28]. - The CDMO market is projected to grow from $63.2 billion in 2021 to $231 billion by 2030, with a compound annual growth rate of 12.5%[31]. - The global active pharmaceutical ingredients (API) market reached $211 billion in 2022 and is projected to grow to $349.2 billion by 2030, with a CAGR of approximately 6.5% from 2023 to 2030[32].

万联证券股份有限公司 关于 宁波美诺华药业股份有限公司 向特定对象发行股票 之 上市保荐书 保荐机构（主承销商） （广州市天河区珠江东路 11 号 18、19 楼全层） 二〇二三年八月 3-2-1 美诺华 2023 年度向特定对象发行股票申请文件 上市保荐书 声 明 万联证券股份有限公司（以下简称"万联证券"或"保荐机构"或"保荐人"） 接受宁波美诺华药业股份有限公司（以下简称"美诺华"或"发行人"）的委托， 担任其 2023 年度向特定对象发行股票的保荐机构。 万联证券股份有限公司及其保荐代表人根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"）等有关 法律、行政法规和中国证券监督管理委员会（以下简称"中国证监会"）、上海证 券交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自 律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书中如无特别说明，相关用语与《宁波美诺华药业股份有限公司 2023 年度向特定对象发行股票募集说明书》中的含义相同。 3-2 ...

特此公告。 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2023-075 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于向特定对象发行股票申请获得上海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日收 到上海证券交易所（以下简称"上交所"）出具的《关于受理宁波美诺华药业股 份有限公司沪市主板上市公司发行证券申请的通知》（上证上审（再融资）〔2023〕 610 号），上交所依据相关规定对公司报送的沪市主板上市公司发行证券的募集 说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法定形式，决 定予以受理并依法进行审核。 公司本次向特定对象发行股票事项尚需上交所审核通过及中国证券监督管 理委员会（以下简称"中国证监会"）作出同意注册决定后方可实施，最终能否 通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在 ...

股票简称：美诺华 股票代码：603538 宁波美诺华药业股份有限公司 Ningbo Menovo Pharmaceutical Co., Ltd. （浙江省宁波市高新区扬帆路 999 弄 1 号 1406 室） 2023 年度向特定对象发行股票 募集说明书 （申报稿） 保荐机构（主承销商） （广州市天河区珠江东路 11 号 18、19 楼全层） 二〇二三年八月 宁波美诺华药业股份有限公司 募集说明书 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整 性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作 ...

万联证券股份有限公司 关于 宁波美诺华药业股份有限公司 2023 年度向特定对象发行股票 之 发行保荐书 保荐机构（主承销商） 二〇二三年八月 美诺华 2023 年度向特定对象发行股票申请文件 发行保荐书 声 明 万联证券股份有限公司（以下简称"万联证券"或"保荐机构"或"保荐人"） 接受宁波美诺华药业股份有限公司（以下简称"美诺华"或"发行人"）的委托， 担任其 2023 年度向特定对象发行股票的保荐机构。 万联证券股份有限公司及其保荐代表人已根据《中华人民共和国公司法》（下 称"《公司法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上 市公司证券发行注册管理办法》（下称"《注册管理办法》"）和《证券发行上 市保荐业务管理办法》（下称"《保荐管理办法》"）等有关法律、行政法规和 中国证券监督管理委员会（下称"中国证监会"）的有关规定，诚实守信，勤勉 尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐 书，并保证所出具文件的真实性、准确性和完整性。 本发行保荐书中如无特别说明，相关用语与《宁波美诺华药业股份有限公司 2023 年度向特定对象发行股票募集说明书》中的含义相同。 3 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2023-074 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 序 | | | 产品 | 产品 | 金额 | 已履行的 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 受托方 | 产品名称 | 类型 | 期限 | （万元） | 审议程序 | | 1 | 交通银行 | 交通银行股份有限公司 2023 年第 90 期企业大额 存单 | 大额 存单 | - | 1,000 | 已经公司2023年4月2 日召开的第四届董事 会第十七次会议、第四 | | | | | | | | 届监事会第十六次会 | | | | | | | | 议，以及 2023 年 4 月 | | | | | | | | 24 日召开的 2022 年年 | | | | | | | | 度股东大会审议通过 | | | 合计 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥246,318,328.09, representing a decrease of 50.76% compared to the same period last year[4] - The net profit attributable to shareholders was ¥43,448,818.81, down 62.30% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,890,801.07, a decline of 89.08% compared to the previous year[4] - Basic earnings per share were ¥0.21, down 72.37% from the previous year[4] - Diluted earnings per share were ¥0.20, a decrease of 71.43% compared to the same period last year[4] - The weighted average return on net assets was 2.06%, a decrease of 4.31 percentage points year-on-year[4] - Total revenue for Q1 2023 was ¥246,318,328.09, a decrease of 50.8% compared to ¥500,209,863.60 in Q1 2022[18] - Net profit for Q1 2023 was ¥46,218,606.15, a decline of 63.6% from ¥126,813,489.39 in Q1 2022[19] - Operating profit for Q1 2023 was ¥56,064,797.51, down 60.9% from ¥143,525,351.09 in Q1 2022[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥16,639,241.51, reflecting a decrease of 131.60% year-on-year[4] - In Q1 2023, the cash inflow from operating activities was CNY 279,804,657.39, a decrease of 27.6% compared to CNY 386,525,685.65 in Q1 2022[22] - The net cash flow from operating activities was negative at CNY -16,639,241.51, contrasting with a positive CNY 52,664,102.21 in the same period last year[22] - Cash inflow from investment activities totaled CNY 291,138,530.74, significantly higher than CNY 94,579,344.47 in Q1 2022[22] - The net cash flow from investment activities was CNY -101,092,484.23, slightly improved from CNY -101,364,941.96 in Q1 2022[22] - Cash inflow from financing activities was CNY 138,468,439.40, down from CNY 196,935,200.00 in the previous year[23] - The net cash flow from financing activities was CNY 23,574,767.30, a decrease of 58.6% compared to CNY 56,829,526.44 in Q1 2022[23] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 468,943,485.90, compared to CNY 380,939,246.25 at the end of Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,427,481,086.30, an increase of 0.18% from the end of the previous year[5] - Total assets as of Q1 2023 were ¥4,427,481,086.30, slightly up from ¥4,419,458,473.75 at the end of Q1 2022[16] - Total liabilities decreased to ¥2,198,904,259.95 in Q1 2023 from ¥2,246,218,288.08 in Q1 2022, a reduction of 2.1%[16] - The company's cash and cash equivalents decreased to RMB 677,394,093.81 from RMB 791,943,106.69, representing a decline of about 14.4%[14] - The company's receivables, including accounts receivable, decreased to RMB 151,742,630.92 from RMB 168,844,670.64, a reduction of about 10.1%[14] Shareholder Information - The top shareholder, Ningbo Meinuohua Holding Group Co., Ltd., holds 21.22% of the shares, totaling 45,285,661 shares[11] - The second-largest shareholder, Yao Chengzhi, owns 5.66% of the shares, amounting to 12,070,253 shares[11] - The company reported a total of 9,080,630 shares held through margin trading by major shareholders[12] Operational Insights - The decrease in revenue was primarily due to a reduction in COVID-related orders and the exclusion of Liao Yuan Pharmaceutical from the consolidated financial statements[8] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[12] - Research and development expenses for Q1 2023 were ¥11,580,047.95, an increase of 35.9% from ¥8,531,863.08 in Q1 2022[19] - The company plans to focus on market expansion and new product development in the upcoming quarters[19] Inventory and Current Assets - As of March 31, 2023, the company's total current assets amounted to RMB 1,924,253,063.05, an increase from RMB 1,894,382,271.16 at the end of 2022, reflecting a growth of approximately 1.9%[14] - The company's inventory increased to RMB 648,072,367.50, up from RMB 594,415,030.12, indicating a rise of approximately 9.0%[14] - The total non-current assets reached RMB 2,113,000,000, with significant investments in fixed assets totaling RMB 1,250,877,425.99[14] - The total amount of trading financial assets increased to RMB 308,899,668.81 from RMB 217,377,643.31, reflecting a growth of approximately 42.2%[14]